CLOs on the Move

Endo

www.endo.com

 
Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo`s strategy is to centralize and unify our business, driving productivity improvements. We will focus ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.endo.com
  • 1400 Atwater Drive
    Malvern, PA USA 19355
  • Phone: 484.216.0000

Executives

Name Title Contact Details
Joseph Barbarite
 Executive Vice President, Global Quality and Compliance Profile
Harris Rotman
 Vice President - Head of Regulatory Affairs, Branded Business Profile
Brian Gorman
 Vice President and Assistant General Counsel Profile
Alexander Nikas
 Vice President and Asst General Counsel Global Commercial Ops and RandD Profile
Susan Williamson
 Senior Vice President and Chief Compliance Officer Profile

Jobs

Chief Information Security Officer

Endo Malvern, PA

Similar Companies

Laboratory Technologies

Laboratory Technologies is a Maple Park, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Serve You

Serve You is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Compass Health Center

Compass Health Center is a well known mental health care providing crisis support for individuals. Avail of our services in Chicago, Illinois!

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.

Creyon Bio

Creyon Bio is a company that is reinventing drug development from the ground up to make safe, effective oligonucleotide based medicines possible—on demand.